ASH 2016 | MPN Landmark studies: looking at the disparities in perceptions of disease and treatment preferences
Claire Harrison, MD, DM, FRCP, FRCPath, of Guy’s and St Thomas’ NHS Foundation Trust, London, UK, discusses the two myeloproliferative neoplasms (MPNs) landmark studies. For the US MPN Landmark study, an update was presented at ASH 2016 with regards to quality of life. Further, another MPN Landmark study looked at patients’ and physicians’ perception of disease and treatment preferences. Interestingly, in the US, there were some disparities between the physicians’ target and the patients’ target. Prof. Harrison mentions an interesting example for patients with polycythemia vera (PV), where the medical perspective is to reduce the risk of blood clots whereas the patient’s perspective is to treat their symptoms and to slow progression of disease. Further, noteworthy data that came from the US Landmark study showed the impact of having a MPN upon the patients’ socio-economic status. The study showed around 20% of patients reducing their hours of work as a consequence of disease, 10% of patients taking on a less intensive job, and 10% of patients taking voluntary redundancy. These results show the real impact on an individual and their family of having this disorder, beyond the conventional medical impacts. Recorded at the 2016 American Society of Hematology (ASH) Annual Meeting, held in San Diego, CA.
Get great new content delivered to your inboxSign up